The real story here is that you have a global India based company that is the giant of generics. And they have manufacturing capabilities that make it so easy to mass produce generics.
So now the India leaders want a presence and some of the big Pharma bright like a guts of the US market.
But they must stay separate fir the most part from their generic side. Meaning they have to separate branded from genetics in their marketing and sales efforts. But you can see their whole purpose is to blend this without anyone noticing.
The 4 therepeutic pillars are Dermatology OPH ONC and Neurology
In the Derm side they have about 400m$ in late stage product cycle cash rich products. There is no more room to grow these drugs though the India culture will spend more money realizing this and as we all know will just raise prices through th the roof.
ONC side is all generic primarily with changes in packaging design and this is their hopeful claim to being branded. Packaging change to make you a high price brand. Hmmmm
OPH a one in a half a dozen eye drop for glaucoma. Allergan and Novartis will crush them in the field.
Neurology an additional sized pill strength in an already crowded market place.
Now they have all these heavy hitter hires from the prestigious big Pharma Companies and they themselves would say and have these drugs we have are weak at best. Matter of fact these were the same drugs and company these new leaders would laugh at when they were at their prestigious companies.
So the game begins. Telling the India leaders what they want to hear. Being the best YES men and woman money can buy. And in the end trying to make lemonade out of lemons.
Get on board and join the fun!
So now the India leaders want a presence and some of the big Pharma bright like a guts of the US market.
But they must stay separate fir the most part from their generic side. Meaning they have to separate branded from genetics in their marketing and sales efforts. But you can see their whole purpose is to blend this without anyone noticing.
The 4 therepeutic pillars are Dermatology OPH ONC and Neurology
In the Derm side they have about 400m$ in late stage product cycle cash rich products. There is no more room to grow these drugs though the India culture will spend more money realizing this and as we all know will just raise prices through th the roof.
ONC side is all generic primarily with changes in packaging design and this is their hopeful claim to being branded. Packaging change to make you a high price brand. Hmmmm
OPH a one in a half a dozen eye drop for glaucoma. Allergan and Novartis will crush them in the field.
Neurology an additional sized pill strength in an already crowded market place.
Now they have all these heavy hitter hires from the prestigious big Pharma Companies and they themselves would say and have these drugs we have are weak at best. Matter of fact these were the same drugs and company these new leaders would laugh at when they were at their prestigious companies.
So the game begins. Telling the India leaders what they want to hear. Being the best YES men and woman money can buy. And in the end trying to make lemonade out of lemons.
Get on board and join the fun!